New Horizons in the Management of MDS
Future perspective on the growing treatment landscape for patients with MDS.
Toxicity Management for Therapies in Lower-Risk MDS
Dr. Garcia-Manero provides an overview of the toxicity profiles for therapies and mitigation strategies for patients with lower-risk MDS.
Approved and Emerging Regimens for Frontline and Second Line Lower-Risk MDS
Guillermo Garcia-Manero, MD, highlights data updates presented at ASH 2023, outlining current and emerging therapies in frontline and second line lower-risk myelodysplastic syndrome (MDS).
Lower-Risk MDS: Current Treatment Landscape and Unmet Needs
Dr Garica-Manero provides a brief overview of the current treatment paradigm for lower-risk MDS as well as discussing some unmet needs.
FDA-Approved Oral Hypomethylating Agent Regimen Excites MDS Landscape
Guillermo Garcia-Manero, MD, discusses how the recently approved combination regimen of decitabine and cedazuridine fits into the treatment landscape for patients with myelodysplastic syndromes.